Search
Exact matches only
Search in title
Search in content
Search in comments
Search in excerpt
Search in posts
Search in pages
Search in groups
Search in users
Search in forums
Filter by Custom Post Type
Filter by Categories
Filter by Report Categories
Advance Interior Materials
Agriculture Industry
Agrochemicals & fertilizers
Animal feed and feed additives
Automotive Sector
Automotive & Transportation
Biotechnology
Building & Construction
Building & Construction Materials
Electronics & Semiconductors
Electronic Devices
Electronic Security
Energy & Resources
Alternative Energy
Distribution & Utilities
Power generation and storage
Food & Beverage
Food Additives and Nutricosmetics
Life Sciences
Healthcare
Wellness
Personal Care & Cosmetics
Materials & Chemicals
Advanced Materials
Advanced Materials (Green Building Materials)
Ceramic & Fiber
Coatings & printing inks
Organic Chemicals
Paints
Petrochemicals
Plastics
Polymers & Resins
Renewable Chemicals
Specialty & Fine Chemicals
Specialty glass
Specialty Polymer
Medical Devices
Pharmaceuticals
Clinic Diagnostics
Technology & Media
Communication Infrastructure
Communication Services
HVAC and Construction
Next Generation Technologies
Textiles
Smart Textiles
{ "homeurl": "https://www.marketresearchandstatistics.com/", "resultstype": "vertical", "resultsposition": "hover", "itemscount": 4, "imagewidth": 70, "imageheight": 70, "resultitemheight": "auto", "showauthor": 0, "showdate": 0, "showdescription": 1, "charcount": 3, "noresultstext": "No results!", "didyoumeantext": "Did you mean:", "defaultImage": "https://www.marketresearchandstatistics.com/wp-content/plugins/ajax-search-pro/img/default.jpg", "highlight": 0, "highlightwholewords": 1, "openToBlank": 0, "scrollToResults": 0, "resultareaclickable": 1, "autocomplete": { "enabled": 1, "googleOnly": 0, "lang": "en" }, "triggerontype": 1, "triggeronclick": 1, "triggeronreturn": 1, "triggerOnFacetChange": 0, "overridewpdefault": 0, "redirectonclick": 1, "redirectClickTo": "results_page", "redirect_on_enter": 1, "redirectEnterTo": "results_page", "redirect_url": "?s={phrase}", "more_redirect_url": "?s={phrase}", "settingsimagepos": "left", "settingsVisible": 0, "hresulthidedesc": "0", "prescontainerheight": "400px", "pshowsubtitle": "0", "pshowdesc": "1", "closeOnDocClick": 1, "iifNoImage": "description", "iiRows": 2, "iiGutter": 5, "iitemsWidth": 200, "iitemsHeight": 200, "iishowOverlay": 1, "iiblurOverlay": 1, "iihideContent": 1, "loaderLocation": "auto", "analytics": 0, "analyticsString": "", "aapl": { "on_click": 0, "on_magnifier": 0, "on_enter": 0, "on_typing": 0 }, "compact": { "enabled": 0, "width": "100%", "closeOnMagnifier": 1, "closeOnDocument": 0, "position": "static", "overlay": 0 }, "animations": { "pc": { "settings": { "anim" : "fadedrop", "dur" : 300 }, "results" : { "anim" : "fadedrop", "dur" : 300 }, "items" : "fadeInDown" }, "mob": { "settings": { "anim" : "fadedrop", "dur" : 300 }, "results" : { "anim" : "fadedrop", "dur" : 300 }, "items" : "voidanim" } }, "autop": { "state": "disabled", "phrase": "", "count": 10 } }

Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2016

$2,000

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2016’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target….

Total Pages: 131

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2016’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
- The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects
- The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hospital Acquired Pneumonia (HAP) Overview 9
Therapeutics Development 10
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Overview 10
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 11
Hospital Acquired Pneumonia (HAP) - Therapeutics under Development by Companies 12
Hospital Acquired Pneumonia (HAP) - Therapeutics under Investigation by Universities/Institutes 14
Hospital Acquired Pneumonia (HAP) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Hospital Acquired Pneumonia (HAP) - Products under Development by Companies 19
Hospital Acquired Pneumonia (HAP) - Products under Investigation by Universities/Institutes 21
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 22
Achaogen Inc. 22
Adenium Biotech ApS 23
Aridis Pharmaceuticals LLC 24
AstraZeneca Plc 25
Cardeas Pharma Corp. 26
MedImmune, LLC 27
Meiji Seika Pharma Co., Ltd. 28
Melinta Therapeutics, Inc 29
Merck & Co., Inc. 30
Motif Bio Plc 31
Nabriva Therapeutics AG 32
Savara Inc. 33
Tetraphase Pharmaceuticals Inc. 34
Wockhardt Limited 35
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
(amikacin + fosfomycin) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(avibactam + ceftazidime) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
(cilastatin sodium + imipenem + relebactam) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
(Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AA-139 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Aerucin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
arbekacin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
delafloxacin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
eravacycline - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
fosfomycin tromethamine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
iclaprim mesylate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
lefamulin acetate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MEDI-3902 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MEDI-4893 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Nu-2 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Panaecin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
panobacumab - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
plazomicin sulfate - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Qn-2251 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
tedizolid phosphate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
tosatoxumab - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
vancomycin hydrochloride - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
WCK-2349 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
WCK-5222 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
WCK-771 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Hospital Acquired Pneumonia (HAP) - Recent Pipeline Updates 91
Hospital Acquired Pneumonia (HAP) - Dormant Projects 121
Hospital Acquired Pneumonia (HAP) - Discontinued Products 122
Hospital Acquired Pneumonia (HAP) - Product Development Milestones 123
Featured News & Press Releases 123
Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 123
Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 123
Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured 123
Oct 13, 2015: Motif Bio Announces Results of Two Posters on Iclaprim at ID Week 2015 124
Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015 125
Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 125
Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia 126
Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA 126
Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline’s Potential Activity in Treating Serious Respiratory Infections 127
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 128
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131

List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2016 10
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Comparative Analysis by Unknown Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc., H1 2016 22
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H1 2016 23
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 24
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2016 25
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp., H1 2016 26
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC, H1 2016 27
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 28
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc, H1 2016 29
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co., Inc., H1 2016 30
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2016 31
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H1 2016 32
Hospital Acquired Pneumonia (HAP) - Pipeline by Savara Inc., H1 2016 33
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 34
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Limited, H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Hospital Acquired Pneumonia (HAP) Therapeutics - Recent Pipeline Updates, H1 2016 91
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2016 121
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2016 122

List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2016 10
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Top 10 Targets, H1 2016 38
Number of Products by Stage and Top 10 Targets, H1 2016 38
Number of Products by Top 10 Mechanism of Actions, H1 2016 40
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 40
Number of Products by Routes of Administration, H1 2016 42
Number of Products by Stage and Routes of Administration, H1 2016 42
Number of Products by Molecule Types, H1 2016 44
Number of Products by Stage and Molecule Types, H1 2016 44


LICENSE TYPE